Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

Roche - Basel

Mixed findings for Roche in Alzheimer’s study

Crenezumab misses targets but shows some signs of activity

- PMLiVE

Priority review for Roche’s Avastin in cervical cancer

Will speed up FDA assessment of oncology drug

Roche - Basel

Roche’s MEK inhibitor boosts Zelboraf efficacy in melanoma

Could give edge to Swiss company as new skin cancer treatments see growth

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

France flag

Pharma criticises France’s backing for off-label Avastin use

EFPIA weighs in on proposal to move wet AMD patients to the drug as a cheaper alternative

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

Japan first to approve Roche’s lung cancer drug alectinib

Personalised medicine has same target as Pfizer’s Xalkori and Novartis’ Zykadia

- PMLiVE

Roche wins In-House Team of the Year at Communiqué Awards

"Brave and courageous" UK communications team picks up honour

- PMLiVE

France wants Avastin used in place of Lucentis

Government calls for off-label use of Roche drug in order to reduce spend on eye therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links